PetMed Express, Inc.

As of June 30, 2026, PetMed Express, Inc. carries a market capitalization of 36.51M, placing it among publicly traded companies globally. Its enterprise value stands at 25.44M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

PetMed Express, Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, PetMed Express, Inc. has 21.68M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.24, and the price-to-book ratio stands at 1.82.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.17 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 25.44M versus a market cap of 36.51M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, PetMed Express, Inc. maintains a current ratio of 0.68, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, PetMed Express, Inc. posted a negative return on equity (ROE) of -78.58, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -33.73, reflecting losses generated across the asset base. The company generates approximately 816,572.69 in revenue per employee across its workforce of 181.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 9.07 indicates how many times PetMed Express, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, PetMed Express, Inc. recorded an income tax benefit of -60,395.70 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -25.69M and -25.63M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, PetMed Express, Inc.'s stock has declined approximately 58.69% over the past 52 weeks. The 50-day moving average sits at 1.36, while the 200-day moving average is 1.87.

Over the twelve months ended June 30, 2026, PetMed Express, Inc. generated 147.80M in revenue and converted that into -25.63M in net income, yielding earnings per share of -1.21. EBITDA reached -18.84M, while operating income came in at -26.94M.

As of June 30, 2026, PetMed Express, Inc. holds 11.45M in cash and equivalents against 362,374.20 in total debt, resulting in a net debt position of -11.45M. Total book value stands at 20.11M, with working capital of -11.37M providing operational flexibility.

PetMed Express, Inc. produced -20.84M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.47M in capital expenditures, free cash flow totaled -24.31M - equivalent to -1.15 per share.

Over the twelve months ended June 30, 2026, PetMed Express, Inc. posted a gross margin of 27.92, reflecting its pricing power and cost economics. The operating margin of -18.22 and net profit margin of -17.34 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, PetMed Express, Inc. paid dividends of 0.00 per share. The dividend payout ratio of -0.07 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -68.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.66, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to PetMed Express, Inc. shareholders.

PetMed Express, Inc.'s most recent stock split took place on March 4, 1999 with a 1:3 split ratio.

As of June 30, 2026, PetMed Express, Inc. has an Altman Z-Score of 1.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.